Research programme: astressins - Sentia Medical Sciences
Latest Information Update: 28 Jun 2023
At a glance
- Originator Sentia Medical Sciences
- Class Antiemetics; Gastrokinetics; Irritable bowel syndrome therapies; Peptides
- Mechanism of Action Corticotropin releasing factor receptor 1 antagonists; Corticotropin releasing factor receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Congenital adrenal hyperplasia; Endocrine disorders; Familial cyclic vomiting syndrome; Gastrointestinal disorders; Gastroparesis; Irritable bowel syndrome; Postoperative ileus; Postoperative nausea and vomiting
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Congenital-adrenal-hyperplasia in USA (Parenteral)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Familial-cyclic-vomiting-syndrome in USA (Parenteral)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Gastroparesis in USA (Parenteral)